Back
Full-text
Journal article

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.

  • Pabst T Department of Medical Oncology and Clinical Research, University Hospital Bern and University Bern, Bern, Switzerland. thomas.pabst@insel.ch
  • Eyholzer M
  • Fos J
  • Mueller BU
  • 2009-03-12
Published in:
  • British journal of cancer. - 2009
Bone Marrow
CCAAT-Enhancer-Binding Proteins
Confidence Intervals
DNA Mutational Analysis
Disease-Free Survival
Genes, Reporter
Humans
Karyotyping
Leukemia, Myeloid, Acute
Leukocyte Count
Luciferases
Mutation
Prognosis
Survival Analysis
Survivors
English CCAAT/enhancer binding protein alpha (CEBPA) mutations in AML are associated with favourable prognosis and are divided into N- and C-terminal mutations. The majority of AML patients have both types of mutations. We assessed the prognostic significance of single (n=7) and double (n=12) CEBPA mutations among 224 AML patients. Double CEBPA mutations conferred a decisively favourable overall (P=0.006) and disease-free survival (P=0.013). However, clinical outcome of patients with single CEBPA mutations was not different from CEBPA wild-type patients. In a multivariable analysis, only double -- but not single -- CEBPA mutations were identified as independent prognostic factors. These findings indicate heterogeneity within AML patients with CEBPA mutations.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/162483
Statistics
Document views: 29 File downloads:
  • Full-text: 0